Results 111 to 120 of about 3,081 (193)

Pretreatment With BTK Inhibitors Improved the Sensitivity of DLBCL Cells to CAR-T Cells in a Coculture System by Downregulating the Polarisation of M2 Macrophages. [PDF]

J Cell Mol Med
Qi Y, Fan X, Wang J, Li X, Mu J, Cui R, Deng Q.   +6 more
europepmc   +1 more source

Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia. [PDF]

Blood Adv
Wu X, Shadman M, Voutsinas J, Hippe DS, Randolph TW, Ujjani CS, Crider C, Keshmiri S, Smith SD, Lynch RC, Di M, Huang JJ, Martin PS, Till BG, Gopal AK.   +14 more
europepmc   +1 more source

P114 | FACTORS INFLUENCING THE REGIMEN CHOICE FOR FIRST-LINE THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA: THE FIRST-CLL STUDY

Haematologica
Treatment options for patients with chronic lymphocytic leukemia (CLL) have significantly increased over the years, and different first-line chemo-free regimens are now available.
F. Perutelli, M. Arata, M.C. Montalbano, R. Minuto, M. Nicolosi, S. Pepe, M. Deodato, E. Fioribello, A. Ferrario, E. Boccellato, R. Moia, M. Bullo, D. Gottardi, M. Foglietta, C. Salvetti, R. Freilone, G. Gaidano, M. Coscia, A.M. Frustaci, F.R. Mauro, B. Bruno, C. Vitale   +21 more
doaj  

P079 | Assessment by high resolution ultrasound sonography of patients with chronic lymphocytic leukemia treated with btk inhibitors (btki). clinical and pharmacoeconomic impact

Haematologica
Introduction. IWCC and ESMO guidelines suggest abdominal ultrasound (US) and superficial lymphonodes (SLN) palpation to assess CLL patients in general practice(GP).
Maria Costanza Caparello
doaj  

Advances in molecular pathobiology of PCNSL - towards clinical implementation of novel diagnostics and therapeutics. [PDF]

Biomark Res
Law YC, Chan JY.
europepmc   +1 more source

Three generations, one target: BTK inhibitors in lymphoma. [PDF]

Blood Adv
Schmitt A, Hailfinger S.
europepmc   +1 more source

HEMOSTATIC ALTERATIONS DURING BRUTON KINASE INHIBITORS TREATMENT

Haematologica
Patients with chronic lymphocytic leukemia (CLL) are at increased risk for major bleeding compared with the general population. The hazard ratio (HR) for major bleeding among 6,717 treated CLL/SLL patients compared with 14816 matched noncancer patients ...
M. Carpenedo
doaj  

Timing matters: Impact of covalent BTK inhibitor dose modifications on outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia-A 7-year real-world study. [PDF]

Cancer
Zhang J, Luo J, Shen X, Ren J, Liu W, Chen L, Jiang L, Weng X, Wang J, Mi JQ.   +9 more
europepmc   +1 more source

PLCG2 exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia. [PDF]

Blood Adv
Qi J, Li W, Dheenadayalan RP, Yosifov DY, Drewes C, Wist M, Wieczorek M, Schmid V, Hobeika E, Gao X, Endres S, Schneider C, Riecke A, Barth H, Gierschik P, Siebert R, Tausch E, Stilgenbauer S, Jebaraj BMC.   +18 more
europepmc   +1 more source

Bruton's tyrosine kinase inhibitor BTKi-2 inhibits mpox virus and vaccinia virus infection. [PDF]

Virol Sin
Yang C, Zhao R, Huo S, Zhang Y, Feng J, Gong M, Zhu L, Zhang C, Zhang L, Xue J, Zhang R, Wang Q, Ding Q.   +12 more
europepmc   +1 more source